Page 120 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 120
Chapter 5
Supplemental Table 4 ICC for normal tissue uptake of Zr-89-mAbs
ICC (lower-upper 95% CI)
Brain Kidney Lung Spleen Liver
Brain Kidney Lung Spleen Liver
Brain Kidney Lung Spleen Liver
Brain Kidney Lung Spleen Liver
89Zr-antiCD20 (37 MBq74inj)
D0
0.92 (0.16-0.99) 1.00 (0.99-1.00) 1.00 (0.99-1.00) 1.00 (0.99-1.00) 1.00 (0.99-1.00)
D0
1.00 (0.97-1.00) 0.99 (0.97-1.00) 1.00 (0.98-1.00) 0.99 (0.96-1.00) 1.00 (0.99-1.00)
D0
1.00 (0.97-1.00) 0.97 (0.85-1.00) 1.00 (1.00-1.00) 0.99 (0.92-1.00) 1.00 (0.99-1.00)
D0
1.00 (0.99-1.00) 1.00 (0.99-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
D3
0.99 (0.90-1.00) 0.99 (0.94-1.00) 1.00 (1.00-1.00) 0.97 (0.81-1.00) 1.00 (0.99-1.00)
D6
0.99 (0.89-1.00) 0.99 (0.85-1.00) 1.00 (1.00-1.00) 0.98 (0.81-1.00) 1.00 (0.99-1.00)
89Zr-antiCD20 (18 MBq74inj)
D3
0.96 (0.73-1.00) 0.98 (0.91-1.00) 1.00 (0.99-1.00) 0.86 (0.39-0.98) 1.00 (0.78-1.00)
D6
1.00 (0.96-1.00) 0.98 (0.83-1.00) 1.00 (0.99-1.00) 0.81 (0.10-0.98) 0.99 (0.94-1.00)
89Zr-antiEGFR (18 MBq37inj)
D3
0.99 (0.94-1.00) 0.99 (0.96-1.00) 1.00 (1.00-1.00) 1.00 (0.97-1.00) 1.00 (0.99-1.00)
D6
0.99 (0.97-1.00) 0.97 (0.78-1.00) 1.00 (0.99-1.00) 0.98 (0.89-1.00) 1.00 (1.00-1.00)
89Zr-antiCD44 (18 MBq37inj)
D1
1.00 (1.00-1.00) 1.00 (0.99-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
D4
0.99 (0.97-1.00) 0.98 (0.93-0.99) 0.99 (0.97-1.00) 1.00 (0.99-1.00) 1.00 (1.00-1.00)
118
